Experimental weight-loss drug outperforms original GLP-1s
Researchers call the compound a 'Trojan horse' that could allow for lower dosages and fewer side effects
New York fitness trainer and gym owner Kenny Santucci discusses concerns about unverified peptide products for muscle building, saying consumers should work with physicians.
A new weight-loss drug variation is showing promise in early trials.
Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani.
The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity , inflammation, fat metabolism and liver health.
'NEXT OZEMPIC' AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS